首页> 外文期刊>BMC Dermatology >Perinatal probiotic supplementation in the prevention of allergy related disease: 6?year follow up of a randomised controlled trial
【24h】

Perinatal probiotic supplementation in the prevention of allergy related disease: 6?year follow up of a randomised controlled trial

机译:围产期益生菌补充剂预防过敏相关疾病:随机对照试验的6年随访

获取原文
       

摘要

Background Perinatal probiotics supplementation has been shown to be effective in the primary prevention of atopic dermatitis (AD) in early childhood, although the long term effects of probiotics on AD and other allergic diseases is less certain. We have previously reported a significant reduction in the cumulative incidence of AD at 2?years after maternal probiotic supplementation. In this study we present the effects of perinatal probiotics given to women from a general population on allergy related diseases in their offspring at 6?years. Methods Four hundred and fifteen pregnant women were randomised to receive probiotic or placebo milk in a double-blinded trial from 36?week gestation until 3?months postpartum. Probiotic milk contained Lactobacillus rhamnosos GG, L. acidophilus La-5 and Bifidobacterium animalis subsp. lactis Bb-12. At 6?years, children were re-assessed for AD, atopic sensitisation, asthma and allergic rhinoconjunctivitis (ARC). Results At 6?years, 81 and 82 children were assessed for AD in the probiotic and placebo groups, respectively. In a multiple imputation analysis, there was as trend towards a lower cumulative incidence of AD in the probiotic group compared to the placebo group (OR 0.64, 95?% CI 0.39-1.07, p?=?0.086; NNT?=?10). This finding was statistically significantly in the complete case analysis (OR 0.48, 95?% CI 0.25-0.92, p?=?0.027, NNT?=?6). The prevalence of asthma and atopic sensitisation, and the cumulative incidence of ARC were not significantly affected by the probiotic regime at 6?years of age. Conclusions Maternal probiotic ingestion alone may be sufficient for long term reduction in the cumulative incidence of AD, but not other allergy related diseases. Trial registration ClinicalTrials.gov identifier: NCT00159523
机译:背景技术尽管益生菌对AD和其他过敏性疾病的长期影响尚不确定,但已证实围产期益生菌补充剂可有效预防儿童早期特应性皮炎(AD)。我们先前曾报道母体补充益生菌后2年,AD的累积发生率显着降低。在这项研究中,我们介绍了一般人群的妇女在6岁时对她们的后代过敏相关疾病的围产期益生菌的影响。方法一项双盲试验从妊娠36周至产后3个月,将515名孕妇随机分配接受益生菌或安慰剂奶。益生菌牛奶包含鼠李糖乳杆菌GG,嗜酸乳杆菌La-5和动物双歧杆菌亚种。乳酸菌Bb-12。在6岁时,对儿童进行AD,特应性致敏,哮喘和变应性鼻结膜炎(ARC)的重新评估。结果在6岁时,益生菌和安慰剂组分别评估了81名和82名儿童的AD。在多重插补分析中,与安慰剂组相比,益生菌组有AD累积发生率降低的趋势(OR 0.64,95%CI 0.39-1.07,p == 0.086; NNT == 10)。 。在整个病例分析中,这一发现具有统计学意义(OR 0.48,95%CI 0.25-0.92,p == 0.027,NNT == 6)。在6岁时,益生菌治疗对哮喘和特应性过敏的患病率以及ARC的累积发生率没有显着影响。结论单独摄入母体益生菌可能足以长期降低AD的累积发生率,但不足以引起其他与过敏相关的疾病。试验注册ClinicalTrials.gov标识符:NCT00159523

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号